PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperphosphatemia |
| Phenotype | C0022658|renal disease |
| Sentences | 8 |
| PubMedID- 23662073 | Background: ferric citrate (fc) is a phosphate binder in development for the treatment of hyperphosphatemia in patients with end-stage renal disease (esrd). |
| PubMedID- 20349415 | To resolve this uncertainty and to determine the most cost-effective way to treat hyperphosphatemia in patients with end-stage renal disease, another randomized study analyzing mortality comparing sevelamer with calcium phosphate binders should be undertaken. |
| PubMedID- 22152168 | Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a us payer perspective. |
| PubMedID- 25150194 | Purpose: sevelamer hydrochloride/carbonate (sh/c) and lanthanum carbonate (lc) are noncalcium-based phosphate binders used for the management of hyperphosphatemia in patients with end-stage renal disease (esrd). |
| PubMedID- 24307220 | Introduction: sevelamer hydrochloride (sh) and lanthanum carbonate (lc) are calcium-free phosphate binders used for the management of hyperphosphatemia in patients with end-stage renal disease (esrd). |
| PubMedID- 25242077 | Ferric citrate (zerenex, keryx biopharmaceuticals, inc.), a phosphate binder drug candidate, recently completed a phase iii program confirming efficacy and demonstrating safety when used to treat hyperphosphatemia in patients with end-stage renal disease. |
| PubMedID- 25069799 | Purpose: sevelamer hydrochloride (sh) and lanthanum carbonate (lc) are calcium-free phosphate binders used in the clinical management of hyperphosphatemia in patients with end-stage renal disease (esrd). |
| PubMedID- 23087550 | hyperphosphatemia is common in patients with end-stage renal disease. |
Page: 1